Nurix partners with Roche on BTK degrader bexobrutideg for up to $2.3B
Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, receiving $700 million upfront plus up to $2.3 billion in milestone payments. The partnership combines Nurix's protein degradation technology with Roche's clinical expe
View filing at SEC.gov →